Development and validation of a pharmacokinetic model of flucloxacillin for dosing in patients with impaired renal function

Development and validation of a pharmacokinetic model of flucloxacillin for dosing in patients with impaired renal function - PK-model Flucloxacillin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41120

Enrollment

Registered

2014-06-05

Start date

2015-01-07

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nierfunctiestoornissen impaired renal function

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - adults treated with oral or intravenous flucloxacillin - normal and impaired renal function expressed as MDRD and corrected for BSA (body surface area)

Exclusion criteria

Exclusion criteria: - patients younger than 18 years of age; - legally incapable patients; - contra-indication or allergy to the treatment with flucloxacillin; - pregnant patients; - patients receiving dialysis.

Design outcomes

Primary

Measure	Time frame
Main study endpoint is the development of a PK-model for dosing of flucloxacillin in patients with impaired renal function.	—

Secondary

Measure	Time frame
Secondary endpoint is the predictive value of the model for dosing of flucloxacillin in patients with impaired renal function.	—

Countries

Netherlands

Outcome results